Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a randomized, double-blind U.S. trial in 375 healthy adults, both 16 and 64 mg doses of TAK-375 produced significantly shorter
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury